首页> 美国卫生研究院文献>Evidence-based Complementary and Alternative Medicine : eCAM >Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on Amyloid β1−40-Induced Alzheimers Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of Amyloid β
【2h】

Therapeutic Effect of Yi-Chi-Tsung-Ming-Tang on Amyloid β1−40-Induced Alzheimers Disease-Like Phenotype via an Increase of Acetylcholine and Decrease of Amyloid β

机译:益智宗明汤对β淀粉样蛋白的治疗作用通过乙酰胆碱的增加和淀粉样蛋白β的减少诱导1-40诱导的阿尔茨海默氏病样表型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder characterized by amyloid accumulation, neuronal death, and cognitive impairments. Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine and has never been used to enhance cognitive function and treat neurodegenerative disorders such as senile dementia. Whether YCTMT has a beneficial role in improving learning and memory in AD patients remains unclear. The present study showed that oral administration of YCTMT ameliorated amyloid-β- (Aβ 1−40) injection-induced learning and memory impairments in rats, examined using passive avoidance and Morris water-maze tests. Immunostaining and Western Blot results showed that continuous Aβ 1−40 infusion caused amyloid accumulation and decreased acetylcholine level in hippocampus. Oral administration of medium and high dose of YCTMT 7 days after the Aβ 1−40 infusion decreased amyloid accumulation area and reversed acetylcholine decline in the Aβ 1−40-injected hippocampus, suggesting that YCTMT might inhibit Aβ plague accumulation and rescue reduced acetylcholine expression. This study has provided evidence on the beneficial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that YCTMT may offer an alternative strategy for treating AD.
机译:阿尔茨海默氏病(AD)是一种不可逆的神经退行性疾病,其特征是淀粉样蛋白积累,神经元死亡和认知障碍。易智聪明堂(YCTMT)是传统中药,从未用于增强认知功能和治疗老年性痴呆等神经退行性疾病。 YCTMT是否在改善AD患者的学习和记忆方面是否具有有益作用尚不清楚。本研究表明,通过被动回避和莫里斯水迷宫测试,YCTMT口服可减轻大鼠淀粉样蛋白-β-(Aβ1-40)注射引起的学习和记忆障碍。免疫染色和Western Blot结果表明,连续输注Aβ1-40会导致海马淀粉样蛋白积聚并降低乙酰胆碱水平。在Aβ1-40输注后7天口服大剂量的YCTMT可以减少注射Aβ1-40的海马的淀粉样蛋白积累面积并逆转乙酰胆碱的下降,这表明YCTMT可能抑制Aβ鼠疫的积累并挽救乙酰胆碱表达的降低。该研究提供了关于YCTMT在改善淀粉样蛋白诱导的AD样症状中的有益作用的证据,表明YCTMT可能提供治疗AD的替代策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号